NCT04600999.

Study name	Clinical trial of favipiravir treatment of patients with COVID‐19
Methods	Open‐label RCT
Participants	SARS‐CoV‐2 infected patients (COVID‐19 patients) with mild pneumonia
Interventions	Experimental: favipiravir from Day 1 plus supportive care (symptomatic therapy): a regimen of 3600 mg (1800 mg twice a day orally) loading dose on Day 1 followed by 1600 mg maintenance dose (800 mg twice a day orally) on Day 2 to Day 14 Control: supportive care
Outcomes	Primary Time to improvement in body temperature Time to improvement in SpO2 Time to imrovement in chest imaging findings Time to imrovement in negative SARS Co‐V‐2 Secondary Change in patient status on 5‐point scale Changes in the level of SARS‐CoV‐2 viral genome SARS‐CoV‐2 virus genome clearance rate Duration of pyrexia Change in clinical symptoms Change in NEWS score Change in chest imaging findings on on Days 4, 7, 10, 13, 16, 19, 22, 25, 28 Percentage of participants requiring adjuvant oxygen therapy Adjuvant oxygen therapy average duration Percentage of participants requiring mechanical ventilation therapy
Starting date	07 October 2020
Contact information	István Várkonyi Institute of Infectology University of Debrecen
Notes